



Leading The Way in Phytocannabinoid Derived Medicines
with a Seed to Medicine Strategy

Company Presentation
November 2019

Disclaimer

The information contained in these slides and the accompanying verbal presentation (“Presentation”) is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, “MGC”). By accepting this Presentation, you agree to be bound by the following limitations.

The content of the Presentation has not been approved by an authorised person within the meaning of the FSMA. This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC’s other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities

This Presentation is exempt from the general restriction set out in section 21 of the Financial Services and Markets Act 2000 (as amended) (“FSMA”) on the communication of financial promotions on the grounds that it is directed only to persons having professional experience in matters relating to investments who fall within the definition of investment professionals in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”); or high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Persons of any other description, including those that do not have professional experience in matters relating to investment, should not rely or act upon this Presentation.

Canaccord Genuity Limited, who is authorised and regulated by the Financial Conduct Authority in the United Kingdom, are acting only for MGC and are not acting for or advising any other person, or treating any other person (whether or not as a recipient of this Presentation) as their client. Canaccord Genuity Limited will not be responsible for providing regulatory protection afforded to their clients or advice to any other person in relation to the Presentation. Any other person receiving the Presentation should seek their own independent legal, investment and tax advice as they see fit.

The information in this Presentation or on which this Presentation is based has been obtained from sources that MGC believes to be reliable and accurate. However, none of MGC, MGC’s directors, officers, employees, its shareholders or any of their respective advisors, or any other person has independently verified the information in this presentation and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions.

Neither Canaccord Genuity Limited, MGC, nor their respective related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

The Presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or used for any other purpose. By accepting delivery of this Presentation, each recipient agrees to treat this Presentation as strictly confidential and not to reproduce, distribute or otherwise use this Presentation or any of its contents without the prior written consent of MGC

Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute “forward-looking statements” or statements about “future matters”, the information reflects MGC’s intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation may not be distributed, published, reproduced or otherwise made available to any other person, in whole or in part, for any purposes whatsoever. In particular, it should not be distributed to or otherwise made available to persons with addresses in Canada, Australia, Japan, the Republic of South Africa or the United States, its territories or possessions or in any other jurisdiction outside of the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting this Presentation, you agree to be bound by the provisions, the limitations and conditions set out in this disclaimer and, in particular, you have represented, warranted and undertaken that: (i) you are a Relevant Person and you will observe the foregoing provisions, limitations and conditions, (ii) you have read and agree to comply with the contents of this disclaimer; and (iii) you agree to keep permanently confidential the information contained in the Presentation or made available in connection with further enquiries to the extent such information is not made publicly available (otherwise through a breach by you of this provision).

Investment Highlights

MGC Pharma is a European based bio-pharma company supplying GMP Phytocannabinoid derived products to patients in UK and Australia

- ✓ Two Investigational Medicinal Products (IMP's) targeting medical conditions: epilepsy, dementia and Alzheimer's disease
- ✓ Additional targeted products in development pipeline
- ✓ Growing patient base in Australia and the UK
- ✓ EU-GMP certified manufacturing facility in Slovenia, manufacturing phytocannabinoid derived products
- ✓ Global distribution via extensive network of commercial partners
- ✓ Highly qualified management team, supported by leading scientific experts
- ✓ Construction has been authorised with site planning completed in Malta for a multi-story building
 - ✓ 10,480m² combined manufacturing facility including GMP certified processing and production
 - ✓ 5,240m² greenhouse on the roof for cultivation

Global Presence

United Kingdom:

- European Corporate Headquarters
- Planned LSE Standard dual listing Q1 2020

Slovenia: Primary Research Base

- Botanical and Pharma research base
- Manufacturing centre with EU GMP certification

Malta: Primary Operation Base (Under Construction)

- Main EU production facility
- Research & Development
- Cultivation facility

Australia: R&D HUB & Corporate HQ

- Corporate and Financial office
- ASX Listed since 2016
- R&D HUB with RMIT

In Numbers

Established EU-GMP licence, operational in the cannabis for medicinal purposes space

2

Operations
Facilities

Malta (under construction) &
Slovenia

Over 15

Years of Collective
Experience in Medical
Cannabis Research

R&D team backed by extensive
industry experience

2

Developed IMP
Products

And pipeline of potential
products in development

Network of
over 30
International
Partners

Cannabis for
Medicinal use
value to reach
~£51bn
(AU\$91.3bn) in
2024

More than
1,000
Prescriptions Issued
in 4 months in 2
jurisdictions

Global Market




Estimated cannabis for medicinal use value
~£51 billion
in 2024



Europe to be largest medical cannabis market.
Total healthcare spend:
£2.1t



Nov 1st 2018
UK legalised prescription
of medical cannabis
products



- MGC Pharma aims to secure a significant share in the global Cannabis Pharmaceutical Market
- MGC Pharma targets large markets, where cannabis for medical use is likely to have a high degree of success
- 2 pharmaceutical products in late stage development

Board of Directors

Highly qualified team with over 15 years of relevant experience



Roby Zomer
Managing Director, CEO & Co.
Founder

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.



Brett Mitchell
Executive Chairman

With over 20 years of experience in the founding, financing and management of both private and publicly listed companies, Mr. Mitchell is responsible for the corporate strategy, capital markets and financial management of the company, and is integrally involved in assisting in building a new industry from the ground up in Australia.



Nativ Segev
Director, Head of Business
Strategy & Founder

The founder of MGC Pharma, previously CEO of a Israeli licensed Medical Cannabis company, with over 10 years of experience in the global medical cannabis industry and over 15 years of experience in executive roles. Founded MGC Pharma to expand into the International markets and to raise the quality and viability of medicinal phytocannabinoid products.



Dr. Stephen Parker
Director & Chairman of Audit,
Risk, Nomination and
Remuneration Committees

Dr. Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America. Dr. Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution.







Dr. Ross Walker
Director &
Head of Medical Advisory Board

Dr. Walker is a well-known figure in Australian health, as former host of a weekly radio programme and a prominent cardiologist who specialises in echocardiography and preventative cardiology. Dr. Walker has published several books, and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.


Clinical Advisory Team

Leading experts in the medical cannabis space with unparalleled expertise

| | | | |
|---|--|--|--|
|  |  |  |  |
| Dr Jonathan Grunfeld | Professor Uri Kramer Head of Neurology product development | Professor David Neubauer | Professor Nadya Lisovoder |
| Certified in Israel, with clinical experience at the MD Andersen Cancer Center, [Prof]. Grunfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology. | One of the few medical professionals in the world to have run full scale epilepsy trials with Cannabis, Dr. Kramer brings a wealth of experience in various fields (Neurology, Pediatric Neurology, Adolescent Psychology & Child Development). Additionally, Professor Kramer is a Former president of the Israeli League Against Epilepsy, giving him unique insight into the daily struggles of the patients his research benefits. | As Head of Department of Child, Adolescent and Developmental Neurology at University Children's Hospital, Ljubljana, Dr Neubauer is widely published and respected, and has dealt with children and adolescents in Neurological contexts for more than thirty years. | 15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been a clinical adviser to public biotech companies as well as incubator companies. She has managed clinical trials and has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies. |

Mission

Building a global bio-pharma company With: Standardised, Affordable Phytocannabinoid Derived Medicines



Company Snapshot

MGC Pharma is at the forefront of Global Phytocannabinoid derived medicines

FIRST PRODUCT TO MARKET

- CannEpil® is a phytocannabinoid product aimed at **drug-resistant epilepsy**
- Being provided to patients in Australia and UK as Investigational Medicinal Products via the **early access schemes** ahead of registration
- Price point and **efficacy** will make it a strong alternative to current medicines

RESEARCH EXCELLENCE

- Landmark collaboration agreement signed between MGC, RMIT and the Hebrew University to establish **CannaHub**
- Establishing the **International Library of Cannabinoids** focusing on research on melanoma and prostate cancer
- Developing the **CannEpil® App**



QUALIFIED MANUFACTURING

- **EU-GMP certification** granted at Slovenian facility for production of phytocannabinoid based Investigational Medicinal Products (Europe)
- MGC facilities are **unique** in Europe, allowing the development of medicines (with API provided)
- **SME approval** by the **European Medicines Agency** (EMA) for scientific advice and incentives

EDUCATION AND PATIENT ACCESS

- Strategic Alliance with Australia's leading epilepsy association, **Epilepsy Action Australia**
- Collaboration on developing **C4E campaign** to increase awareness and access to medication



Seed to Medicine Manufacturing

Creation and commercialisation of Phytocannabinoid derived products through a model utilising R&D capability

Global Operation

- Multi-National base
- EU-GMP certified facility, from provided API to compounded product
- Pharma European R&D HQ in Slovenia
- Cultivation R&D in Slovenia

New Centralised EU Hub

- Maltese Facility to become primary operations hub
- Supply chain with easy access to European markets
- To involve a 10,480m² combined manufacturing facility including GMP certified processing and production, with a 5,240m² greenhouse on the roof for cultivation



CULTIVATION

High THC >35% strains
High CBD >20% Strains



EXTRACTION &
ISOLATION INTO API

Super Critical (Co²)
Alcohol Extraction




CLINICAL TRIALS

Europe (EMA)
Australia (TGA)



PRODUCT
DEVELOPMENT

Europe
Australia
Israel



DISTRIBUTION

UK
Australia

Commercial Production: Malta – a Centralised Hub

Establishing a fully integrated medical cannabis “Seed to Medicine” operation in the EU

Signed long-term lease on 6,000m² site for full medical cannabis facility providing direct access to the EU

One of the first cannabis industry companies to sign a long-term lease agreement with the Maltese government to develop a fully integrated GMP compliant medical cannabis production facility in Malta. Facility will include cultivation, production and research of MGC Pharma cannabinoid derived medicines for global distribution.

First federal bill on legalising medicinal cannabis in Malta passed in parliament during March 2018.



Medical Cannabis legalised in Malta – provides direct access to the EU

Malta is highly strategic for the success of the Company's EU focused business and operations plan.


Climate is ideal for cannabis cultivation and allows three crop cycles per year.

As part of the EU, Malta is favourable for the construction of large scale operations.


- MGC will establish turnkey “Seed to Medicine” state-of-the-art EU GMP production facility to provide its medicines globally
- Large scale, eco friendly commercial facility will be a 15,720m² multi-story facility with production capacity of over 8,000 units per hour of each product
- Access to existing operational and distribution pipelines in Europe and Australia
- Direct access to key emerging markets through the FDA Mutual Recognition agreement signed with Austria, Croatia, France, Italy, Malta, Spain, Sweden and the UK

Malta facility – Architectural Design of Malta Hub

Front view




Side view





MGC Research & Development

3 research areas based on medical experience and large data collections



Investigational Medicinal Products

Targeting specific medical conditions such as epilepsy and dementia



FURTHER PRODUCT PIPELINE

Pipeline of phytocannabinoid derived products, APIs and unique formulations all manufactured under GMP certified facilities to be used in pharmaceutical treatment and research

CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy

CANN EPIL®

- Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes

Target Market:

- Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in UK)
- Over 200,000 epilepsy patients in Australia
- Approximately 25% of people with epilepsy have a drug-resistant (DRA) form
- Estimated population at launch of marketing authorisation is over 200,000 people with DRA (in Europe and Australia)
- Expected time to marketing authorisation 4 years

CannEpil® is an oral oil solution of 20:1 cannabidiol (CBD) and (-)- trans- Δ^9 -tetrahydrocannabinol (THC).

Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

MGC's first pharmaceutical-grade product targeted for drug resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy.

Estimated yearly average treatment costs per patient: £6,000-£8,000

Neurological Disorders

Epilepsy

The global epilepsy market is expected to be ~£7.3bn by 2023

CogniCann™

CogniCann™ is MGC Pharma's second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer's disease patients quality of life

COGNICANN™

- Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme

Target Market:

- Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in UK)
- Over 135,000 mild dementia patients in Australia
- Total estimated with mild dementia population 950,000 at marketing authorisation launch (in Europe and Australia)
- Expected time to marketing authorisation 5 years

CogniCann™ is a oromucosal spray of cannabidiol (CBD) and (-)- trans-Δ9-tetrahydrocannabinol (THC).

Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

Contains a 3:2 mix of THC (25mg/mL) and CBD (17mg/mL)

Estimated yearly average treatment costs per patient : £4,400

Neurological Disorders

Dementia

The global dementia medication market is expected to exceed ~£23bn by 2026

Research and Development – Potential Products

- Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Europe and Australia
- Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals

NEUROLOGICAL

CepaCann Oral Spray to treat Cerebral Palsy

Preclinical in process

ONCOLOGICAL & CANCER SIDE EFFECTS

Tetrinol Treatment of Anorexia Cachexia in Cancer Patients

MXOT02GB01 Treatment of Glioblastoma (NIB)

MXOT02ME01 Treatment of Melanoma Cancer (RMIT/CannaHub)

MXOT02PC01 Treatment of Prostate Cancer (RMIT/CannaHub)

Preclinical in process

AUTOIMMUNE DISEASE – INFLAMMATORY

InCann BiActive Capsule to treat Chron's and IBS (RMIT/CannaHub)

Preclinical in process

TopiCann Topical treatment of Eczema and inflamed skin (RMIT/CannaHub)


Study Results: 70% Reduction in 4 weeks



Strategic Partnership with RMIT



MGC Pharma and RMIT developing CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC)



CannaHub provides an interface connecting doctors and patients with clinical research and information on cannabinoid sequences and their potential treatments

INTERNATIONAL LIBRARY OF CANNABINOIDS

- ILC is the World's first library of cannabis medicine where details of medical cannabis clinical research, cannabinoid sequences and their treatments can be found
- ILC will collect data from diverse clinical studies, academic publications, patient feedback as well as diverse cannabinoid strains
- Collected and analysed data from the ILC will assist and enhance the work of doctors and researchers and improve industry efficacy estimates of cannabinoid treatment of various disorders
- ILC could be utilised for the design and implementation of clinical trials via its mobile and web-based applications

Other Strategic Partnerships: Cultivation & Production

CULTIVATION

- Active engagement with multiple cultivation sites to meet increasing global demand
- Specialised controlled cultivation also underway for research into breeding and genetics, in partnership with leading institutions and academia
- Raw material used for extraction and isolation into Active Pharmaceutical Ingredients (API)

OBJECTIVE: To refine and regulate MGC's genetic bank to guarantee the ability to produce flawless, high quality products globally

Key Partnerships:

- University of Ljubljana – Bio faculty – research into the development of new genetic strains
- IHPS (HOP institute Slovenia) – research into the improvement of technical growing parameters
- Safe Pharma Macedonia – commercial cultivation partner

Jurisdictions:

- 2016-18 Czech Republic
- Slovenia and, Malta from 2021

PRODUCTION

- Production of high quality pharmaceutical products to be used as part of a prescribed medical treatment plan
- Pharmaceutical products initially targeting treatment of epilepsy, IQL in dementia and Alzheimer's, Oncological care and Autoimmune diseases
- Also includes compounding of phytocannabinoid based API

OBJECTIVE: The production of high quality, consistent, cost effective medicines targeting common illnesses and diseases

Key Partnerships:

- University of Ljubljana – Clinical Centre – Research in Epilepsy
- National Institute of Biology (NIB) – Research in Brain Cancer
- Royal Melbourne Institute of Technology (RMIT) - Research in Brain Cancer and Autoimmune diseases

Jurisdictions:

- Slovenia, Australia and upcoming, Malta

Key Wholesaler Partner

LENIS – A FULL-SERVICE PHARMACEUTICAL DISTRIBUTOR

Lenis specializes in the distribution of unlicensed drugs and niche therapeutic areas (licensed in the source country but not in the destination country). This includes:

- New drugs not yet approved in a country
- Discontinued cost-effective drugs (e.g. infertility, ophthalmology, infectious diseases)
- Product alternatives during drug shortages (e.g. oncology)
- Comparator drugs for clinical trials

Lenis provides added value products in niche therapeutic areas and the distribution of innovative pharmaceutical products and generic pharmaceuticals with limited number of competitors.

Lenis is the Company's wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets.

Its core principal is Gilead Sciences, Inc.

Lenis partnership provides the Company with:

- Knowledge on regulatory affairs
- Market access
- Medical Support
- Marketing & Sales
- Wholesale & Distribution
- Pharmacovigilance



Key Distribution Partners


Extensive network in place providing access to hospitals, pharmacies and research institutions around the world

SOUTH AMERICA



Distributor has a disruptive digital strategy to capture leads of potential patients and connect them with the physicians they need

EUROPE



Distribution channels with a strong distribution network of over 5,500 pharmacies that can fulfil prescriptions direct to a patient's door



Mexacare provides the sales, marketing and logistics for diagnostic devices and complementary medical products to pharmacies, labs, hospitals and doctors



AFRICA




Founded in 1978, AM MANGION has grown into a top-ranking healthcare company Distributor of Gilead Sciences, Inc and J&J

ASIA



AUSTRALIA




Health House specialist as wholesales and distributes of medical cannabis to and in Australia



Cannvalate has a network of over 1,000 doctors and 600 pharmacies across Australia

Projected Timelines

Working to achieve values over time as “Seed to Medicine” Bio-Pharma Company



Investment Case

Fully Integrated Model: Grow → Develop → Commercialise



Built on Decades of Experience

Technical team of globally recognised scientists and doctors

Focussed Operations

Core divisions:

Research and Development

Manufacturing and Distribution

Strategically Located

Operational bases close to key markets supported by corporate headquarters

Robust Product Offering

Portfolio of established and upcoming products targeting key markets

International Reach

Network of research and commercial partners globally

Strong Market Outlook

Global phytocannabinoid market gaining traction




 <https://mgcpharma.com.au/>

 @mgcpharmaceuticals

 @MGC_Pharma

 MGC Pharmaceuticals, Ltd.

Financial PR:

 St Brides Partners
(+44) 02072361177

info@stbridespartners.co.uk